June 26 (Reuters) - Nippon Shinyaku Co Ltd 4516.T:

• ELIXIRGEN THERAPEUTICS AND NIPPON SHINYAKU ENTER INTO AN OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF EXG-7001 FOR DUCHENNE MUSCULAR DYSTROPHY

• ELIXIRGEN THERAPEUTICS: WILL RECEIVE UPFRONT PAYMENT, IS ELIGIBLE FOR ADDITIONAL DEVELOPMENT AND SALES-BASED MILESTONE PAYMENTS

• ELIXIRGEN THERAPEUTICS: NIPPON SHINYAKU MAY OBTAIN EXCLUSIVE WORLDWIDE RIGHTS TO COMMERCIALIZE EXG-7001

• ELIXIRGEN THERAPEUTICS: NIPPON SHINYAKU WILL PROVIDE FUNDING FOR DEVELOPMENTAL COSTS

Source text: ID:nGNX7W5mG0

Further company coverage: 4516.T